Podcasts about fda approval

I'm joined by Dr. Heather Hirsch to debunk the persistent myths surrounding hormone replacement therapy and explain why the 2002 Women's Health Initiative data was so widely misinterpreted. We discuss how optimized estrogen, progesterone, and testosterone levels can protect your heart, bones, and brain health, helping you move past "normalized suffering" and into a proactive state of longevity. Whether you are in perimenopause or well past the ten-year window, you'll learn how to navigate personalized dosing and clinical data to reclaim your vitality and extend your health span.Want ad-free episodes? Subscribe to Forever Strong Insider: https://bit.ly/4u5VSReListen to “Women's Health by Heather Hirsch, MD” on all your favorite platforms!Apple Podcasts: https://bit.ly/4l86MlwSpotify: https://bit.ly/4cpmiHuGet Dr. Heather Hirsch's book, “The Perimenopause Survival Guide” here:https://bit.ly/4r2yXUd

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

"Why are we paying $10,000 for a $30 drug?"My guest this week is Pramod John, a former Silicon Valley tech entrepreneur who entered the healthcare space to tackle the largest economic problem in the country: skyrocketing healthcare costs. Pramod quickly realized that healthcare's dysfunction is actually not a technology problem - it is a deeply ingrained problem with economic incentives.In this episode, we dive into the murky waters of Pharmacy Benefit Managers (PBMs) and why the traditional model is designed to drive up costs rather than lower them. We discuss the shocking statistics of drug spend (where 2% of people account for 55% of the costs), why FDA approval doesn't always mean a drug is effective (using the infamous Alzheimer's drug as an example), and the implications of recent fiduciary lawsuits like the one against J&J.Pramod explains how we can bring common sense back to healthcare by treating drugs like any other consumer purchase. By utilizing an "open market" drug management model, he argues that we can effectively replace traditional PBMs with transparent transaction processing software - saving plans 30% to 50% without relying on restrictive formularies or rebate games. Tune in this week for a clear roadmap for how to actually fix the irrational economics of our healthcare system.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit ParetoHealth.com to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Why We Talk About Cost Instead of Quality (00:02:42) From Silicon Valley & Defense Tech to McKesson (00:10:43) Why Healthcare is NOT a Technology Problem (00:15:53) Fiduciary Responsibility & The J&J Lawsuit (00:19:03) The Butter Knife vs. Pareto: The Math of Drug Spend (00:23:54) Building an "Open Market" Alternative to PBMs (00:29:40) Why Doctors Fly Blind on Drug Pricing & Formularies (00:35:42) FDA Approval vs. Real-World Efficacy (00:45:44) How to Actually Fix the Model: The Real-Time "Pause" (00:58:36) Why International Sourcing & PAPs Aren't the Fix (01:11:00) Replacing PBMs with Simple Transaction SoftwareKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

"Why are we paying $10,000 for a $30 drug?"My guest this week is Pramod John, a former Silicon Valley tech entrepreneur who entered the healthcare space to tackle the largest economic problem in the country: skyrocketing healthcare costs. Pramod quickly realized that healthcare's dysfunction is actually not a technology problem - it is a deeply ingrained problem with economic incentives.In this episode, we dive into the murky waters of Pharmacy Benefit Managers (PBMs) and why the traditional model is designed to drive up costs rather than lower them. We discuss the shocking statistics of drug spend (where 2% of people account for 55% of the costs), why FDA approval doesn't always mean a drug is effective (using the infamous Alzheimer's drug as an example), and the implications of recent fiduciary lawsuits like the one against J&J.Pramod explains how we can bring common sense back to healthcare by treating drugs like any other consumer purchase. By utilizing an "open market" drug management model, he argues that we can effectively replace traditional PBMs with transparent transaction processing software - saving plans 30% to 50% without relying on restrictive formularies or rebate games. Tune in this week for a clear roadmap for how to actually fix the irrational economics of our healthcare system.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit ParetoHealth.com to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Why We Talk About Cost Instead of Quality (00:02:42) From Silicon Valley & Defense Tech to McKesson (00:10:43) Why Healthcare is NOT a Technology Problem (00:15:53) Fiduciary Responsibility & The J&J Lawsuit (00:19:03) The Butter Knife vs. Pareto: The Math of Drug Spend (00:23:54) Building an "Open Market" Alternative to PBMs (00:29:40) Why Doctors Fly Blind on Drug Pricing & Formularies (00:35:42) FDA Approval vs. Real-World Efficacy (00:45:44) How to Actually Fix the Model: The Real-Time "Pause" (00:58:36) Why International Sourcing & PAPs Aren't the Fix (01:11:00) Replacing PBMs with Simple Transaction SoftwareKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

In today's episode, we spoke with Alexander I. Spira, MD, PhD, FACP, FASCO. Dr Spira is co-director of the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, director of the VCS Thoracic and Phase I Program, chief scientific officer of NEXT Oncology, and a clinical assistant professor at Johns Hopkins University in Baltimore, Maryland.In our exclusive interview, Dr Spira discussed the significance of the December 2025 FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), also known as subcutaneous amivantamab, for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) across all approved indications for amivantamab-vmjw (Rybrevant). He noted key data from the pivotal phase 3 PALOMA-3 trial (NCT05388669), which showed that subcutaneous amivantamab combined with lazertinib (Lazcluze) had a more favorable safety profile compared with intravenous (IV) amivantamab plus lazertinib and was noninferior to the IV formulation in terms of efficacy. Dr Spira contextualized these trial findings within the larger EGFR-mutated NSCLC treatment paradigm and explained how this formulation of amivantamab addresses a previously unmet patient need.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Send a textThe landscape of hormone replacement therapy (HRT) and other medications is constantly evolving. Recently, the black box warning on HRT was removed, highlighting the importance of context when evaluating drug safety. From post-finasteride syndrome to FDA approval nuances, and the safety of compounding pharmacies, this guide explains what patients and providers need to know to make informed choices about hormonal and non-hormonal therapies.What You'll Learn in This Video1️⃣ HRT Black Box Update – Why the warning was removed and what it means for patients.2️⃣ Post-Finasteride Syndrome – Risks, neurological and sexual side effects, and global regulatory responses.3️⃣ FDA Approval vs. Safety – Why FDA approval doesn't always mean a product is risk-free.4️⃣ Compounding Pharmacy Regulation – How compounding works, safety standards, and legal customization of therapies.5️⃣ Non-Hormonal Options – Combining ingredients like DHEA, vitamins, and hyaluronic acid for safe, tailored alternatives.

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56. Key topics included: • The design and findings of the DESTINY-Breast09 trial • Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane) • The implications of these findings for clinical practice • The role of maintenance therapy and the potential for personalized treatment strategies • Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease) Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/  Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a whirlwind of activity in the industry, where scientific breakthroughs, regulatory shifts, and strategic collaborations are all reshaping the future of healthcare.Let's start with a look at the ongoing efforts by the Trump administration to negotiate Medicare drug prices under the Inflation Reduction Act. This initiative is set to impact 15 high-profile drugs, marking a significant push towards more stringent pricing regulations. The aim is to make medications more affordable for patients, but this move could also compel pharmaceutical companies to rethink their pricing strategies and revenue models. Such regulatory changes underscore a broader trend toward cost containment in healthcare, a critical issue as drug prices continue to be a major concern for policymakers and consumers alike. Additionally, proposed changes to Medicare Advantage rates by the Trump administration could lead to benefit cuts or market exits by insurers, highlighting ongoing uncertainties in healthcare financing that could significantly impact patient access to care.In the realm of oncology, Johnson & Johnson has achieved another milestone with its Darzalex Faspro. This drug has received FDA approval for an expanded indication in treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplants. This approval is not just a regulatory win; it reflects the growing importance of combination therapies in enhancing treatment outcomes for complex diseases like multiple myeloma. The shift towards combination regimens is a notable trend in oncology, aiming to maximize therapeutic efficacy and improve patient survival rates.Meanwhile, Teva Pharmaceuticals is bracing for a potential slowdown come 2026 after a period of growth. This projection highlights the inherent volatility in the pharmaceutical market, where external factors such as regulatory changes and competitive pressures can swiftly alter financial trajectories. Companies like Teva must remain agile and adaptable to navigate these unpredictable waters.On the innovation front, Cellares has secured $257 million in a Series D funding round aimed at expanding its cell therapy contract manufacturing operations globally. This significant investment underscores an increasing demand for advanced therapeutic manufacturing capabilities, reflecting the industry's pivot towards personalized medicine and cell-based therapies. As the landscape of medicine shifts towards more individualized approaches, companies like Cellares are positioning themselves at the forefront of this transformative trend.Novo Nordisk is actively exploring new growth avenues, with its business development head engaging in numerous strategic meetings at the J.P. Morgan Healthcare Conference. This proactive approach illustrates how critical partnerships and acquisitions are becoming for pharmaceutical companies looking to maintain a competitive edge and drive innovation forward. Novo Nordisk's pursuit of Metsera aligns with broader industry trends where strategic acquisitions are leveraged to bolster pipelines with innovative therapies.Pfizer continues to dominate the vaccine production arena despite challenging market conditions that have seen competitors like Sanofi face setbacks. This leadership can be attributed to Pfizer's robust product pipeline and strong relationships with healthcare providers, highlighting how trust and reliability remain crucial components of success in this field.In gene therapy news, Eli Lilly has forged a $1.1 billion agreement with Seamless Therapeutics aimed at developing gene-editing medications for hearing loss. This collaboration is indicative of gene therapy's expanding scope, offering hope for addressing previously untreatable conditions Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory challenges, and strategic investments that are shaping the future of healthcare.Let's begin with Moderna's recent decision to halt its late-stage vaccine trials, a move reflective of a broader trend of vaccine hesitancy in the United States. Moderna's CEO Stéphane Bancel pointed to shifts in government policy and an increasing public skepticism towards vaccines as pivotal reasons for this decision. This development signals a potential slowdown in vaccine research and development investments across the industry. The implications are profound, as vaccine hesitancy could impact public health initiatives and the readiness to tackle future pandemics.In parallel developments, Sanofi is navigating its own set of challenges with its eczema treatment. Despite plans to file for FDA approval for its OX40 blocker following the Phase III COAST 2 trial, results were mixed, echoing earlier data that analysts found underwhelming. This situation highlights the inherent uncertainties in drug development and raises questions about the treatment's potential market success. As Sanofi persists, the broader industry is reminded of the complexities involved in bringing new therapies to market, particularly in dermatology where unmet needs remain significant.Meanwhile, Chinese biotech firm Corxel has secured an impressive $287 million in Series D1 funding to push forward its oral GLP-1 therapy, CX11. This funding will support its mid-stage development in the US and preparations for Phase III studies. The investment underscores a robust interest in GLP-1 therapies known for their efficacy in treating type 2 diabetes and obesity. The competitive landscape for these therapies is heating up, with major players vying for market dominance through novel delivery mechanisms and enhanced patient outcomes. Notably, Novo Nordisk's oral Wegovy is advancing while Eli Lilly's Orforglipron faces delays, highlighting the strategic importance of timely development and market entry in capturing lucrative opportunities within this therapeutic area.On the regulatory front, a notable legislative challenge has emerged with the failure to reauthorize the FDA's rare pediatric disease priority review voucher program for 2024. Advocates are calling for its reinstatement given its critical role in incentivizing the development of rare disease treatments through expedited review processes. Such regulatory changes underscore the delicate balance between encouraging innovation and ensuring rigorous standards, a dynamic that continuously shapes R&D strategies within the industry.In oncology, Bristol Myers Squibb is making headlines with an $850 million investment in Janux Therapeutics' tumor-activated drugs. This significant investment reaffirms BMS's commitment to pioneering cancer therapies that promise better patient outcomes through innovative mechanisms of action. The focus on oncology reflects a broader industry trend towards precision medicine and targeted treatments aimed at improving efficacy while minimizing side effects.As we pivot to manufacturing developments, Lotte Biologics is expanding its capabilities with plans to launch its Syracuse ADC hub by 2026. This expansion aligns with global efforts to enhance manufacturing quality and capacity, crucial factors as biopharmaceuticals become more complex and demand increases.Turning our attention to financial achievements within the industry, Samsung Biologics has reached a historic milestone by becoming the first Korean biopharmaceutical company to surpass a profit threshold of 2 trillion won ($1.36 billion). This accomplishment spotlights the growing influence of contract manufacturing organizations (CMOs) like Samsung BiologicsSupport the show

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention. Key topics discussed included: • The definition and classification of smoldering myeloma • The design and findings of the AQUILA trial • The significance of time to progression and overall survival in treatment • The risk-benefit analysis of daratumumab therapy, including potential side effects • Future directions in myeloma treatment and ongoing research Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!

In this new episode of Bathroom Diaries, I sit down with Dr. Rob Frankel, emergency physician, anti-aging specialist, and host of the Modern Man Podcast, for an honest, science-forward conversation about one of the most talked-about tools in modern longevity: peptides. But this isn't hype. This episode goes beyond TikTok trends and biohacking buzzwords. We unpack what peptides actually are, how they work inside the body, who should (and should not) be using them, and why precision and medical integrity matter more than ever in this space. Dr. Frankel explains peptides as "text messages" to your cells, signals that enhance your body's own intelligence rather than override it. We explore where peptide therapy shows real promise, where caution is essential, and how innovation can coexist with responsibility. In this episode, we talk about: * What peptides really do at a cellular level * The difference between enhancement vs. "sledgehammer" medicine * GLP-1s, Tesamorelin, BPC-157, NAD, GHK Copper & more * Peptides for metabolism, recovery, cognition, skin & longevity * Why not every body is a candidate * The danger of self-prescribing from the internet * How peptides fit into a whole-body, intelligent aging strategy This conversation is for anyone curious about longevity, aesthetics, metabolic health, and the future of personalized medicine, without the smoke and mirrors. Because aging well isn't about chasing trends. It's about understanding your biology and guiding it wisely.   00:00 Introduction: Peptides, Longevity & Medical Integrity 02:05 Meet Dr. Rob Frankel (ER Physician & Anti-Aging Specialist) 04:30 What Peptides Actually Are (Simple Biology Explained) 07:10 Peptides as "Text Messages" to Your Cells 10:15 Peptides vs Traditional Medicine (Signal vs Sledgehammer) 13:40 GLP-1 Peptides & Metabolic Health 17:30 FDA Approval, Safety & the Gray Areas of Peptides 21:10 Tesamorelin: Visceral Fat, Growth Hormone & Longevity 25:10 CJC & Growth Hormone Signaling 28:20 BPC-157 & TB-500 for Recovery and Inflammation  32:00 Cognitive Peptides: BDNF, C-Max & Brain Performance  36:20 Peptide Dosing, Monitoring & Blood Work 39:30 NAD Explained: Energy, Krebs Cycle & Cellular Aging  44:00 NAD Safety, Cancer Risk & Proper Cycling  47:10 GHK Copper Peptides for Skin, Hair & Aesthetics 51:20 Do Peptides Enhance Botox, Fillers & Laser Results?  54:10 Cost of Peptide Therapy & Cycling Strategy 56:40 Who Should NOT Use Peptides 59:20 Peptides, Menopause, Andropause & Hormonal Health 01:03:10 The Future of Personalized & Systems Medicine 01:05:10 Rapid Fire: Most Overhyped & Underrated Peptides 01:07:30 Final Thoughts: Aging Intelligently

TechCrunch Disrupt Battlefield 2023 winner, Biotics AI, announced on Monday that it has received FDA clearance for its AI software that helps detect fetal abnormalities in ultrasound images. Also, Sequoia Capital is reportedly joining a blockbuster funding round for Anthropic, the AI startup behind Claude, according to the Financial Times. It's a move sure to turn heads in Silicon Valley. Why? Because venture capital firms have historically avoided backing competing companies in the same sector. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In today's episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066).In this exclusive interview, Dr Falchi discussed why this approval is clinically meaningful—establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome. He also placed EPCORE FL-1 in the broader epcoritamab development program, referencing supportive experience with the phase 1/2 EPCORE NHL-2 trial (NCT04663347) and ongoing efforts to move bispecific antibody–based regimens earlier in the treatment paradigm through the phase 3 EPCORE FL-2 trial (NCT06191744).any of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today's episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we delve into the year 2025, it's clear that the pharmaceutical and biotech industries have been navigating a complex landscape filled with both challenges and remarkable advancements. Despite regulatory uncertainties and broader economic fluctuations, the FDA approved 55 new treatments and vaccines this year. Although this figure represents a slight decline from previous years, it underscores the sector's resilience and steadfast commitment to innovation even amid external pressures.One significant development in oncology comes from Incyte, which is advancing its application for FDA approval of a seven-drug Monjuvi regimen as a first-line treatment for diffuse large B-cell lymphoma. This move is backed by positive Phase 3 trial results, highlighting Monjuvi's potential to enhance treatment options for this aggressive cancer type. However, Incyte may face hurdles in gaining regulatory approval and achieving commercial success, reflecting the competitive nature of oncology therapeutics.In obesity management, Novo Nordisk introduced its once-daily Wegovy pill in the U.S., marking a milestone in the field. Priced at $149 per month for cash-paying patients with potential discounts for those insured, Wegovy's launch could shift market dynamics significantly by offering a more accessible treatment option. This aligns with the growing global focus on obesity as a critical public health issue.The industry also saw substantial investments to bolster manufacturing capabilities. Daiichi Sankyo announced plans to invest $1.9 billion to expand Enhertu production facilities across countries such as the United States, China, Japan, and Germany. This strategic move aims to strengthen supply chain robustness and meet anticipated demand for Enhertu, a pivotal player in cancer therapeutics. Meanwhile, economic pressures are palpable as drugmakers raised prices on over 350 products at the start of the year, surpassing previous years' increases. This reflects ongoing tensions around drug pricing policies and affordability, posing challenges for industry stakeholders and patients alike.The labor landscape within biopharma has been affected as well, with layoffs increasing by 16% year-over-year in 2025. These reductions highlight ongoing cost-cutting measures amid financial uncertainties and strategic realignments within companies. Yet, strategic partnerships continue to shape research and development efforts, particularly in autoimmune diseases. Sanofi's collaboration with AI biotech Earendil Labs could potentially reach $2.5 billion, emphasizing the increasing role of artificial intelligence in drug discovery and development processes. These collaborations are poised to accelerate advancements in personalized medicine and innovative therapeutic approaches.Regulatory activities have also seen notable developments this year. GSK's Nucala received approval for treating COPD in China, expanding its therapeutic scope beyond asthma. This regulatory progress signifies opportunities for existing drugs to access new markets and indications. However, the National Institutes of Health faced leadership challenges with the departure of its National Institute of Neurological Disorders and Stroke director. This adds to a series of leadership changes across NIH institutes, raising concerns about stability within this pivotal organization responsible for advancing medical research.Turning now to significant scientific advancements and clinical trials, promising results emerged from studies focused on cellular energy boosters aimed at treating Alzheimer's disease. A molecule that restores cellular energy was shown to reverse cognitive decline in mice with advanced Alzheimer's, suggesting a potential new class of therapeutics for this debilitating condition. Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events that are shaping the landscape of this dynamic industry. The ever-evolving arena of drug approvals, regulatory challenges, and strategic shifts continues to captivate stakeholders across the globe.Sanofi's recent acquisition of Dynavax for $2.2 billion illustrates a prevailing trend within the sector—mergers and acquisitions aimed at expanding vaccine portfolios in response to global health priorities. This strategic move provides Sanofi with access to Heplisav-B, a hepatitis B vaccine, thereby reinforcing the importance of broadening vaccine offerings amid ongoing global health concerns.The U.S. Food and Drug Administration (FDA) has been active in granting approvals for new therapies, reflecting ongoing efforts to address a wide range of medical needs. Agios Pharmaceuticals has received approval for Aqvesme, a treatment designed specifically for anemia in patients with either alpha- or beta-thalassemia. Meanwhile, Vanda Pharmaceuticals has secured approval for Nereus, a novel motion sickness treatment. These approvals highlight the FDA's dedication to advancing treatments for both common and rare medical conditions.A noteworthy milestone was achieved by Omeros Corporation as it secured FDA approval for Yartemlea—its first U.S. approval in 31 years. This drug is a novel treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, underscoring the industry's focus on developing therapies for niche yet critical medical conditions.Verastem Oncology has opted to halt its phase 1/2 trial of a KRAS G12C inhibitor targeting non-small cell lung cancer due to increasing competition from next-generation inhibitors. This decision reflects the competitive and rapidly evolving landscape of oncology therapeutics where companies must adapt their strategies based on interim data and market dynamics.Foresee Pharmaceuticals has reported promising phase 3 results for Camcevi in treating central precocious puberty (CPP), a rare hormonal disorder. This demonstrates the potential for repurposing established drugs to address unmet needs in pediatric endocrinology.Inflarx is actively exploring partnerships to revitalize its C5a antibody vilobelimab which was initially developed for pyoderma gangrenosum but faced setbacks after a terminated phase 3 trial. The company's persistence in seeking new pathways forward exemplifies the challenges and resilience required in drug development, especially for rare diseases.Regulatory hurdles remain a significant challenge as illustrated by Outlook Therapeutics' ophthalmic bevacizumab facing another FDA rejection. Such outcomes emphasize the stringent regulatory environment that companies must navigate to bring innovative therapies to market.A federal judge's temporary pause on the 340B rebate pilot underscores ongoing legal and regulatory debates impacting healthcare policy and industry operations. The contentious rollout of this pilot reflects broader tensions between administrative actions and healthcare stakeholders.As we look forward, industry analysts anticipate that the surge in mergers and acquisitions observed in late 2025 will persist into 2026. Companies are driven by growth aspirations through strategic acquisitions aimed at expanding their pipelines and market reach.Despite positive advancements, some companies face setbacks. Johnson & Johnson's discontinuation of its $1.2 billion eczema therapy due to unsatisfactory clinical results highlights the inherent risks and unpredictability of drug development. Similarly, Genmab's withdrawal of a cancer drug from development underscores these challenges within oncology research.In contrast, Neuralink's plans to ramp up production of its brain-computer interface devices highliSupport the show

On this episode of #mensexpleasure, Cam is joined by his brother Callum to explore the story of Geddings David Osbon, an automotive shop worker from South Carolina who invented the penis pump. Key points:01:33 Geddings' Early Life and Family09:50 The Birth of the Penis Pump17:52 Challenges and Acceptance25:33 FDA Approval and Market Breakthrough30:05 Family Legacy and Business Expansion43:09 Third Generation and Modern Era44:52 Reflections and Final Thoughts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into some of the latest breakthroughs and shifts shaping the industry landscape.In recent weeks, the pharmaceutical world has been abuzz with news of a groundbreaking new therapy that offers hope for patients with a rare genetic disorder. This novel treatment utilizes cutting-edge gene-editing technology, specifically CRISPR-Cas9, to target and correct genetic mutations at their source. By precisely editing the DNA within patient cells, this therapy promises not only to alleviate symptoms but potentially cure the disorder altogether. The implications of this development are profound, as it opens new avenues for treating a host of other genetic diseases that have long been considered incurable. Researchers are optimistic that this could herald a new era in personalized medicine.Meanwhile, on the regulatory front, significant progress has been made with the approval of a new cancer drug by the FDA. This drug, which has shown remarkable efficacy in clinical trials, targets a specific protein that is overexpressed in certain types of tumors. By inhibiting this protein, the drug effectively halts tumor growth and reduces metastasis. Such targeted therapies represent a shift towards more precise cancer treatments, minimizing damage to healthy cells and reducing side effects for patients. The FDA's decision underscores the importance of innovative approaches in oncology and sets a precedent for future approvals.In another exciting development, a recent phase III clinical trial has yielded promising results for a new Alzheimer's treatment. This monoclonal antibody targets amyloid-beta plaques in the brain, which are believed to be a key factor in the progression of Alzheimer's disease. The trial showed significant slowing of cognitive decline in patients who received the treatment compared to those on placebo. While there is still much to learn about the pathogenesis of Alzheimer's, these findings offer renewed hope for patients and their families and highlight the potential for antibody-based therapies in neurodegenerative diseases.Turning our attention to industry trends, there's a growing emphasis on sustainability within pharmaceutical manufacturing processes. Many companies are now investing in green chemistry, which focuses on designing products and processes that minimize environmental impact and reduce waste. This shift is not only driven by regulatory pressures but also by increasing consumer demand for eco-friendly products. By adopting sustainable practices, pharmaceutical companies are working to ensure that their contributions to global health do not come at the expense of planetary health.Finally, let's explore an intriguing trend within biotech: the rise of artificial intelligence (AI) and machine learning in drug discovery. These technologies are being harnessed to analyze vast datasets more efficiently than ever before, enabling researchers to identify potential drug candidates with greater speed and accuracy. AI-driven platforms can model complex biological interactions, predict molecular behavior, and even design novel compounds. As this field continues to evolve, it promises to revolutionize how new drugs are discovered and developed, potentially reducing time-to-market and bringing therapies to patients faster.These stories illustrate just how dynamic and innovative the pharmaceutical and biotech industries continue to be. With every breakthrough and development, there comes new hope for tackling some of humanity's most challenging health issues. Thank you for joining us today on Pharma Daily as we continue to explore these exciting advancements in science and medicine.Support the show

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

In today's episode, the discussion features Christof Vulsteke, MD, PhD, head of the Integrated Cancer Center Ghent in Belgium, who provided clinical and regulatory insight into the KEYNOTE-905 study (NCT03924895) and the November 2025 FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC). In this exclusive interview, Dr Vulsteke outlined the scientific rationale and study design of KEYNOTE-905, reviewed the key efficacy and safety findings observed with the enfortumab vedotin/pembrolizumab combination, and discussed how the safety profile of this combination aligns with prior experience in bladder cancer. He also contextualized the significance of this FDA approval in addressing a longstanding unmet need for cisplatin-ineligible patients and highlighted remaining gaps in care, including global access, patient selection, and future research directions aimed at improving outcomes in this challenging-to-treat population.

What are your thoughts on the efficacy of strontium for bone health?What to you think of HRT for bone health?I have aortic valve stenosis. Is there any alternative to surgery?I have dry eyes after cataract surgeryAre there any benefits to Deer Antler for increasing HGH?

For dark days, get some sun in your eyesThe misleading vegan diet twin studyA least favorite thing from one of our listeners

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we are diving into a series of significant breakthroughs and updates that are shaping the industry landscape.Starting with a remarkable scientific advancement, researchers have made headway in the development of a new class of antibiotics that shows promise against drug-resistant bacteria. This comes as a beacon of hope in the ongoing battle against superbugs, a problem that has been escalating over the past few decades. The new antibiotics work by targeting bacterial cell walls in a novel way, which may bypass the resistance mechanisms that have rendered many traditional antibiotics ineffective. This innovation could potentially extend the lifespan of existing drugs and provide new treatment options for infections that are currently difficult to manage. It's crucial to monitor how these developments will proceed through clinical trials and regulatory scrutiny, as successful outcomes could revolutionize our approach to bacterial infections.Shifting focus to regulatory news, the FDA has recently approved a groundbreaking gene therapy for a rare genetic disorder affecting children. The therapy is designed to target and correct specific genetic mutations, offering hope for families affected by this debilitating condition. This approval not only marks a milestone for personalized medicine but also sets a precedent for future gene therapies targeting other rare diseases. The implications of such advancements are vast, as they open doors to tailored treatments that address the root causes of genetic disorders rather than just managing symptoms. As we continue to explore the potential of gene editing technologies like CRISPR, it's important to consider both the ethical and logistical challenges that accompany these scientific leaps.In clinical trial news, a late-stage study has shown promising results for a new cancer immunotherapy targeting non-small cell lung cancer. This therapy leverages the body's immune system to identify and destroy cancer cells more effectively than traditional treatments. The trial demonstrated significant improvements in patient survival rates and quality of life, underscoring the potential of immunotherapies to transform oncology care. These findings add to a growing body of evidence supporting immunotherapy as a cornerstone of future cancer treatment regimens. However, it is essential to continue researching how these therapies can be optimally combined with existing treatments to enhance outcomes and minimize side effects.Turning our attention to industry trends, there is an increasing emphasis on digital health solutions in drug development processes. Pharmaceutical companies are integrating artificial intelligence and machine learning technologies to streamline clinical trials and accelerate drug discovery. These digital tools enable more efficient data analysis, patient monitoring, and predictive modeling, which can significantly reduce development timelines and costs. As this trend gains momentum, it will be important to assess how these technologies can be best utilized without compromising data integrity or patient safety.Lastly, let's discuss an interesting development in sustainable biomanufacturing practices. Companies are investing in greener production methods that reduce environmental impact while maintaining high-quality standards for pharmaceuticals. This includes optimizing energy use, minimizing waste, and incorporating renewable resources into manufacturing processes. As regulatory bodies increasingly prioritize sustainability, we can expect these practices to become more widespread across the industry.These stories highlight how innovation continues to drive progress within pharmaceuticals and biotechnology, offering new possibilities for treatment and care. As always, it's eSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Pharmacist Steve Giroux on FDA approval of the Wegovy pill full 318 Wed, 24 Dec 2025 09:45:00 +0000 MXSahP2UGClnVQe0mcVdz86DrWs0trjT news & politics,news WBEN Extras news & politics,news Pharmacist Steve Giroux on FDA approval of the Wegovy pill Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcasting

Dr. Ashley Bernotas of Kaleida Health Weight Management Center on FDA approval of Wegovy pill full 251 Wed, 24 Dec 2025 09:45:00 +0000 ylB3qvtkWp3O32YPG2FAsScKqLddUd1y news & politics,news WBEN Extras news & politics,news Dr. Ashley Bernotas of Kaleida Health Weight Management Center on FDA approval of Wegovy pill Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False

Market update for Tuesday December 23, 2025Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In this episode:Gold and silver prices hit new recordsNovo's weight-loss pill gets FDA approvalGoogle buys a renewable energy firm for $4.75BTrump's new battleship deal goes to Huntington IngallsU.S. drone stocks soar after U.S. bans foreign playersJohnson & Johnson ordered to pay $1.5B by jury in baby powder case

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/17/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v70yuz6","div":"rumble_v70yuz6"}); Video Source Links (In Chronological Order): Support The Last American Vagabond Trump EPA Nearly Doubles Threshold for Safe Formaldehyde Exposure — ProPublica Susie Wiles, Trump's Chief of Staff, Criticizes Bondi and Vance in Candid Interviews - The New York Times New Tab (5) Mehdi (e/λ) on X: "I believe DARPA just launched the most audacious bioengineering program of the decade & nobody's talking about it loud enough I spent hours reading through the Generative Optogenetics program documentation & honestly I'm still processing the implications of what they're trying https://t.co/1Uh0VsUz8F" / X GO: Generative Optogenetics | DARPA Generative Optogenetics (GO) Overview - YouTube New Tab DARPA 'Generative Optogenetics (GO)' Seeks to Program Living Cells Using Light, Could Aid in 'Extended Human Spaceflight' Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives - PMC Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy | Nature Communications News: Optogenetics and mRNA Vaccines Net... (The Scientist) - Behind the headlines - NLM Optogenetics: We may soon be able to manipulate the mind with light - Genetic Literacy Project Coronavirus Gives a Dangerous Boost to DARPA's Darkest Agenda New Tab Can Magnetism Help Us Control the Brain, Remotely? - University at Buffalo Magnetogenetics and the Future of Remote Biological Control RFK Jr. wants everyone to use wearables. What are the benefits, risks? - ABC News Evaluating methods and protocols of ferritin-based magnetogenetics - ScienceDirect Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates | bioRxiv Flipping a Switch Inside the Head - Seek : Seek Genetically engineered 'Magneto' protein remotely controls brain and behaviour | Science | The Guardian The field of neurogenetics: where it stands and where it is going - PMC Biodigital Convergence, COVID Magnetogenetic Ferritin Vaccines & Big Spikes In Mass Vaccinated Areas Bob Langer The Coronavirus "Common Denominator" Tied To Charles Lieber & Israel's NY "Smart Cities" Charles Lieber's nanoscale transistors can enter cells without harming them | Harvard Magazine Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | Pfizer (8) John Beaudoin, Sr., The Real CdC, The Last Boomer on X: "Please repost How can they just ignore 18,000 kidney deaths in ONE state? @zoeharcombe @_Esther4_14 @Earthdriver @unhealthytruth @elonmusk @EmeraldRobinson @jqe22 @CartlandDavid @GenFlynn @thevivafrei @RobertKennedyJr @JimFergusonUK @LizGunnNZ @FluoridePoison @RepMTG" / X Trump Admin Leans Into Self-Amplifying mRNA (SamRNA) Under Guise Of Ending mRNA & RNA In Food New Tab (8) The Last American Vagabond on X: "With the #6G news, be sure to read @DBrozeLiveFree's article breaking down what this really means & how little they care about the health & environmental side effects—in fact they have baked into their bills that these factors cannot even be considered. https://t.co/ZNwOTZhMEy" / X Trump's FCC Seeks to Strip Even More Local Control Over 5G Rollout (8) ADAM on X: "BREAKING:

CHEST 2025 showcased exciting advances in interstitial lung disease treatment, featuring new anti-fibrotic therapies and more personalized approaches. Drs. Adegunsoye and Kaul discuss emerging strategies for earlier detection and more targeted interventions across different lung disease phenotypes.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of pivotal events shaping the landscape of drug development and patient care. The interplay between scientific advancements, regulatory shifts, and strategic partnerships is setting the stage for significant transformations within the industry.A highlight of recent developments is the legal challenge faced by Merck & Co. regarding its new subcutaneous version of Keytruda. This immunotherapy, already a breakthrough in cancer treatment, has encountered a hurdle in Germany where Halozyme, known for its drug-delivery technologies, has secured a preliminary injunction. This move by a German court halts Merck's activities related to Keytruda SC in Germany and underscores the intricate web of intellectual property rights in drug launches across international markets. The outcome of this case could establish crucial precedents for future commercialization efforts involving advanced drug delivery technologies.Meanwhile, there's promising news from Bristol Myers Squibb as their CAR-T therapy, Breyanzi, receives its fifth FDA approval, this time for marginal zone lymphoma. This approval is particularly noteworthy as it marks Breyanzi as the first CAR-T treatment sanctioned for this specific indication and extends its use across five different types of blood cancers. CAR-T therapies continue to represent a frontier in cancer treatment by leveraging the body's immune system to combat malignancies more effectively. This success story from Bristol Myers Squibb highlights the expanding potential of CAR-T therapies in tackling various hematological cancers, offering renewed hope for patients with limited treatment avenues.On the regulatory front, the FDA's proposal to consider single-trial approvals for certain drugs has sparked considerable debate. While some industry voices express concerns about potential compromises to safety and efficacy standards, others see it as an opportunity to invigorate research and development investments by reducing both time and costs associated with bringing new therapies to market. This shift could indeed accelerate innovation but will necessitate a careful balance to uphold rigorous safety standards.In parallel regulatory news, Daiichi Sankyo has received an "untitled letter" from the FDA over its patient ambassador video for Turalio, indicating ongoing challenges in navigating drug promotion guidelines and patient engagement strategies. Such interactions emphasize the complexities pharmaceutical companies face within regulatory frameworks.Shifting focus to corporate strategies, Mark Cuban's Cost Plus Drugs is exploring a partnership with Humana aimed at addressing prescription drug costs for employers. This collaboration seeks to reduce healthcare expenses through innovative pricing models and distribution channels, reflecting a broader industry trend toward cost containment and value-based care delivery.In another development affecting public health policy, the CDC's Advisory Committee on Immunization Practices has postponed its vote on changes to newborn hepatitis B vaccine policies due to ongoing debates and confusion surrounding the topic. This delay highlights the intricate nature of updating long-standing public health policies, especially those impacting vaccination schedules.From an investment perspective, Freenome's decision to go public through a $330 million SPAC deal stands out. Specializing in developing blood tests for early cancer detection using machine learning technologies, Freenome's move aims to secure capital necessary for advancing its diagnostic tools—potentially transforming cancer screening practices by enabling earlier detection and intervention.In clinical trial news, Praxis Precision Medicines reported positive efficacy results from a Phase 2 trialSupport the show

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/5/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v70gta2","div":"rumble_v70gta2"}); Video Source Links (In Chronological Order): (26) Brook Jackson

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

Dr. Hoffman continues his conversation with Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes.”

The Revolutionary Role of the Vagus Nerve in Bioelectronic Medicine: Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes,” details the historical context and recent advancements in harnessing the power of the vagus nerve to control inflammation without causing immunosuppression. The conversation explores the journey from early experimental stages to the recent FDA approval for treating rheumatoid arthritis through vagus nerve stimulation (VNS) devices. He also delves into the potential applications of VNS in treating other inflammatory conditions, mood disorders, and the science behind non-invasive lifestyle techniques and commercially available devices. The episode provides valuable insights into the future of bioelectronic medicine and its potential to revolutionize medical treatments.

Tinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma. Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including: • The significance of the study in the context of recent FDA approvals and treatment advancements. • Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab. • The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes. • Management of side effects and clinical pearls for practitioners. We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions. Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more practice-changing updates in oncology! #MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Harry P. Erba, MD, PhD, about the FDA approval of ziftomenib (Komzifti) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Dr Erba is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute in Durham, North Carolina. In our exclusive interview, Dr Erba discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1/2 KOMET-001 trial (NCT04067336), and the role ziftomenib may play throughout the evolution of the AML treatment paradigm. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast is supported by funding, however, content is produced and independently developed by OncLive.

Bioelectronic medicine is changing how we treat inflammation, autoimmunity, and chronic disease, and this episode shows you exactly how nerve stimulation could redefine human performance, longevity, and brain optimization. You will learn how electricity, neurotransmitters, and targeted neural pathways can replace drugs, control inflammation, and help you hack the vagus nerve with precision instead of guesswork. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey is joined by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, pioneer of vagus nerve research, and author of The Great Nerve. He is one of the world's most cited scientists in inflammation and neuroscience, and his discoveries created the field now known as bioelectronic medicine. He identified the therapeutic action of anti TNF antibodies, mapped the inflammatory reflex, and revealed how vagus nerve signaling controls immunity. With more than 450 scientific publications and over 120 U.S. patents, he is a trusted authority whose work drives the future of anti-aging, functional medicine, metabolism, and neural therapies. Dr. Tracey and Host Dave Asprey explore how the vagus nerve truly operates, why it contains 200,000 fibers with different functions, and what happens when you stimulate specific pathways that regulate inflammation, HRV, neurotransmitters, and immune signaling. You will learn how nerve impulses transmit information, how voltage gated ion channels shape behavior and biology, and why certain forms of stimulation create measurable improvements in mitochondria, metabolic control, sleep optimization, and emotional regulation. They break down the science behind surgical vagus nerve implants, focused ultrasound, gamma entrainment, cytokine control, and real neuromodulation. They also explore why cold plunging, breath work, HRV training, nootropics, and consumer devices vary so widely in their effects, and how to evaluate these tools with practical biohacking frameworks. You will hear what actually works, what remains experimental, and what the next decade of nerve based therapies could unlock for brain optimization, longevity, ketosis, fasting, supplements, and AI guided interventions in human biology. You'll Learn: • How vagus nerve stimulation reduces inflammation through the inflammatory reflex • Why bioelectronic medicine can replace drugs in autoimmune conditions • How nerve fibers relay electrical and chemical signals inside the body • Why cold immersion, breath work, and HRV training activate specific vagal pathways • How 40 hertz gamma entrainment may influence cognitive decline • Which stimulation methods have clinical validation and which do not • Why high vagal tone is linked to better metabolism, immunity, and emotional stability • What future nerve based technologies may unlock for human performance Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Kevin J. Tracey, vagus nerve stimulation, bioelectronic medicine, inflammatory reflex, SetPoint Medical, cytokine control, neuromodulation therapy, autonomic nervous system, HRV optimization, inflammation reduction, rheumatoid arthritis treatment, focused ultrasound therapy, gamma entrainment, mitochondrial signaling, anti-aging science, neural pathway hacking, functional medicine research, immune system regulation, brain and body performance, human longevity science Thank you to our sponsors! -AquaTru | Go to https://aquatruwater.com/daveasprey and save $100 on all AquaTru water purifiers. -MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Calroy | Head to https://calroy.com/dave for an exclusive discount Resources: • Learn More About Kevin's Work: https://feinstein.northwell.edu/institutes-researchers/our-researchers/kevin-j-tracey-md • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 - Trailer 1:12 - Bioelectronic Medicine 3:23 - FDA Approval 6:48 - RA Treatment Explained 11:35 - Vagus Nerve Function 15:12 - External vs Implanted Stimulation 18:06 - Focused Ultrasound 26:11 - Ear Stimulation Science 30:51 - Clinical Evidence 37:10 - Alzheimer's Link 42:15 - Future Applications 46:48 - Cold Exposure Effects 53:51 - Common Misconceptions 55:38 - Final Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).  We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML. Key topics covered in this episode included: The mechanism of action of Ziftomenib as a menin inhibitor Study findings from KOMET-001 and patient response rates Management of side effects, including differentiation syndrome and QTc prolongation Comparison with other menin inhibitors like Revumenib Future directions for combination therapies and sequencing of treatments Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights. #Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Want a legal career blending Intellectual Property (IP), Biotechnology, and Business? We sit down with Jenna Matheny (Vice-President & Managing Director at APIOiX) to break down the path to a high-impact career in medical innovation. This episode is essential listening for law students and those interested in patent law who also have a passion for science, revealing a world of opportunities beyond traditional law firm life.In this episode, we discuss:The Innovation Lifecycle: How lawyers are involved from invention disclosure and patent strategy to regulatory approval (FDA) and commercialization.The Business of IP: The critical, often-overlooked importance of contracting and compliance in developing and licensing medical technology.Finding Your Niche: Jenna's unique career path through university Tech Transfer offices, incubators, and accelerators—and how law students can get their foot in the door.Beyond Science: The growing field of social innovation and how non-science majors can find rewarding IP careers focused on copyright and trademark.Practical Law School Advice: Which broad-based courses (like securities and international tax) set you up for success, and the value of clinics and residencies.(00:00) - Introduction: Blending Law, Science, and Business in an IP Career (01:43) - Meet Jenna Matheny: Expert in Medical Technology IP and Tech Consulting (04:28) - Defining Biotech vs. MedTech: Law's Role in FDA Approval (05:42) - The Core Practice Areas: Patents, Contracting, and Regulatory Compliance (10:09) - Career Pivot: From Medicine Interest to Patent Attorney Path (11:32) - Tech Transfer Offices (TTOs): How Law Students Can Gain Experience (14:28) - Incubators & Accelerators: Consulting and Internship Roles for Attorneys (20:39) - Practical Advice: Essential Law School Courses (Securities, Tax) and Clinics (24:26) - Serendipity & Networking: How Connections Change the Course of a Legal Career (25:59) - Social Innovation: IP Opportunities without a Science Background (Copyright & Trademark) Click here to view the episode transcript.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (11/9/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v6za9zu","div":"rumble_v6za9zu"}); Video Source Links (In Chronological Order): (21) Zachary Foster on X: "Only 1 of 102 antisemitism investigations at US universities over the past 2 years were unrelated to criticism of Israel, according to publicly available data reviewed by @AAUP & @MESA_1966. Mainstream media has manufactured a gigantic antisemitism hoax. https://t.co/CGqxELfB0U https://t.co/Q5VEujbfj0" / X (21) Peter A. McCullough, MD, MPH® on X: "BREAKING: Peer-Reviewed Study Finds COVID-19 "Vaccines" Linked to 63 Serious Brain and Spinal Cord Adverse Events 63 CDC/FDA safety thresholds breached as mRNA-LNP-Spike disrupts the blood–brain barrier, increasing risks of meningitis, encephalitis, prion disease, brain https://t.co/EvEaT82nZQ" / X View of COVID-19 mRNA vaccination: implications for the central nervous system Frontiers | A calibration of nucleic acid (PCR) by antibody (IgG) tests in Germany: the course of SARS-CoV-2 infections estimated You Have Every Reason To Question EVERYTHING You're Told About Variants, Vaccines, Masks & PCR Tests PCR Archives - The Last American Vagabond Faith in Quick Test Leads to Epidemic That Wasn't - The New York Times The PCR Illusion & 'The Epidemic That Wasn't' Pathologist Arne Burkhardt Final Interview - Revealing the Grave Dangers of mRNA Vaccines Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | Pfizer (21) The Last American Vagabond on X: "What happened is they lied to you. As they all do. The real question is whether conservatives will still stand by them despite repeated lies and sell outs." / X (21) X22 Report on X: "Here is a video of the Ozempic executive fainting in front of Trump. Do you see why they are called the fake news? https://t.co/3T5DQ7opnI" / X (21) The Last American Vagabond on X: "So apparently Ozempic, Bill Gates' fake food, and transgenic edible vaccines (and even new COVID shots) are "MAHA"... or is that just what the blind followers say? Speak up conservatives, show the nation that you are not what the #TwoPartyIllusion pretends you are. #Winning" / X Trump Admin Leans Into Self-Amplifying mRNA (SamRNA) Under Guise Of Ending mRNA & RNA In Food New Tab (21) swordofthejedi❤️‍

Most people assume that if a drug sits on the shelf at Costco or Walgreens, it must be pretty safe. But what if some of the most common over-the-counter (OTC) medications are among the riskiest drugs in America? On this episode of Vitality Radio, Jared exposes the hidden dangers behind everyday pain relievers, sleep aids, and heartburn drugs—medicines that cause thousands of deaths every year when misused or taken long-term. You'll learn how a drug becomes “OTC,” what happens when pharmaceutical companies push for that switch, and why the FDA's approval process might not tell the whole story. Jared dives into the startling realities of PPIs like Prilosec, NSAIDs like ibuprofen, and acetaminophen (Tylenol)—uncovering their risks to the liver, kidneys, bones, and brain. He also discusses how marketing convinces consumers these drugs are harmless. Finally, Jared offers a resource for safe, natural alternatives for reflux, pain, inflammation, sleep, and immune support—options that nourish the body instead of depleting it. This episode will change the way you look at “harmless” OTC drugs and help you take real control of your health.Just Ingredients Lemon Swish Protein Powder Vitality Radio POW! Product of the Week $29.99 per bag (regular price $59.99) with PROMO CODE: POW15Additional Information:#341: Your Digestive Health Supplement User's Guide. From IBS to Acid Reflux - Learn How to Balance Your Gut Health With Natural Products. #522: Q&A Show #5 - Jared Answers Your Questions About Energy and Sleep!#471: Boosting Your Immune System Ahead of Winter #553: Boswellia & Curcumin: Nature's Dream Team for Pain & Inflammation with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Israelis celebrate reports of a ceasefire; on Culture Friday, John Stonestreet covers the FDA approval of generic mifepristone and Bari Weiss at CBS; and Collin Garbarino reviews Tron: Ares. Plus, the Friday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from Cedarville University—a Christ-centered, academically rigorous university located in southwest Ohio, equipping students for Gospel impact across every career and calling. Cedarville integrates a biblical worldview into every course in the more than 175 undergraduate and graduate programs students choose from. New online undergraduate degrees through Cedarville Online offer flexible and affordable education grounded in a strong Christian community that fosters both faith and learning. Learn more at cedarville.edu, and explore online programs at cedarville.edu/onlineFrom Covenant College, where Christian faculty equip students for their callings through hard ideas, deep questions, and meaningful work. covenant.edu/worldAnd from Ambassadors Impact Network, helping entrepreneurs who are looking for more than just funding. Discover a community of Christian faith-led investors. More at ambassadorsimpact.com